- Home
- NTB vs IMCR Comparison
NTB vs IMCR Comparison
Compare NTB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- IMCR
- Stock Information
- Founded
- NTB 1858
- IMCR 2008
- Country
- NTB Bermuda
- IMCR United Kingdom
- Employees
- NTB N/A
- IMCR N/A
- Industry
- NTB Commercial Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTB Finance
- IMCR Health Care
- Exchange
- NTB Nasdaq
- IMCR Nasdaq
- Market Cap
- NTB 1.9B
- IMCR 1.8B
- IPO Year
- NTB 2016
- IMCR 2021
- Fundamental
- Price
- NTB $45.25
- IMCR $35.24
- Analyst Decision
- NTB Buy
- IMCR Buy
- Analyst Count
- NTB 3
- IMCR 8
- Target Price
- NTB $51.33
- IMCR $57.00
- AVG Volume (30 Days)
- NTB 163.0K
- IMCR 290.9K
- Earning Date
- NTB 10-21-2025
- IMCR 11-05-2025
- Dividend Yield
- NTB 4.38%
- IMCR N/A
- EPS Growth
- NTB 14.60
- IMCR N/A
- EPS
- NTB 4.96
- IMCR N/A
- Revenue
- NTB $588,897,000.00
- IMCR $356,145,000.00
- Revenue This Year
- NTB $3.31
- IMCR $31.83
- Revenue Next Year
- NTB N/A
- IMCR $8.50
- P/E Ratio
- NTB $9.20
- IMCR N/A
- Revenue Growth
- NTB 2.95
- IMCR 26.78
- 52 Week Low
- NTB $34.77
- IMCR $23.15
- 52 Week High
- NTB $46.89
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- NTB 52.60
- IMCR 56.75
- Support Level
- NTB $44.50
- IMCR $35.33
- Resistance Level
- NTB $45.67
- IMCR $37.16
- Average True Range (ATR)
- NTB 0.84
- IMCR 1.36
- MACD
- NTB 0.06
- IMCR 0.32
- Stochastic Oscillator
- NTB 75.17
- IMCR 53.39
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.